To answer jason_paloalto's question specifically:
From a clinical standpoint, GLP-1 and gluconeogenesis is a reasonable concern that deserves a thorough answer.
The short answer: the evidence supports this approach for most patients.
The longer answer involves reviewing the specific clinical trial data relevant to your question, which I am happy to elaborate on if helpful.